RVMD Revolution Medicines Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
14:18
Nov 07
Nov 07
$RVMD 12% non-SpaceX portfolio holding Portfolio
RVMD
Revolution Medicines
Long
1ST
Position: Holding
—
00:02
Oct 28
Oct 28
CNBC
Let Revolution Medicines keep running
Responding to a long-time shareholder, Cramer says to let Revolution Medicines run because the FDA has become more sensible and that should allow the pancreatic-cancer drug story to keep working. He does not give a detailed fundamental forecast, but the instruction is to stay with the position.
RVMD
Revolution Medicines
Long
1ST
—
—
00:34
Sep 01
Sep 01
CNBC
Revolution Medicines has expanding oncology opportunity.
Yee also likes Revolution Medicines. Its breakthrough pancreatic cancer drug is continuing to make a big impact in lung cancer, making it another major story and an attractive way to play the pharma innovation theme.
RVMD
Revolution Medicines
Long
1ST
—
—
About RVMD Investor Commentary
Across the available history and selected sources, Buzzberg tracks RVMD (Revolution Medicines) across 15 sources: 14 bullish vs 0 bearish calls from 16 authors. Historical directional balance: 23% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 62 total trade ideas tracked. Past 7 days, before deduplication: 1 bullish, 8 other directions. Latest voices: stocksavvyshay, Jim Cramer, Michael Yee.